Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B-Reference-Cited by-同舟云学术

Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B

Published:2023-10-13 Issue:9 Volume:58 Page:965-966
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Huang Rui¹²³^ORCID,Zhang Zhiyi³,Wang Jian¹²,Zhang Shaoqiu¹,Wu Chao¹²³^ORCID

Affiliation:

1. Department of Infectious Diseases Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China

2. Institute of Viruses and Infectious Diseases, Nanjing University Nanjing China

3. Department of Infectious Diseases Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine Nanjing China

Abstract

LINKED CONTENTThis article is linked to Lee et al papers. To view these articles, visit https://doi.org/10.1111/apt.17643 and https://doi.org/10.1111/apt.17711

Funder

Nanjing Medical Science and Technique Development Foundation

Natural Science Foundation of Jiangsu Province

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.17712

Reference10 articles.

1. Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non‐cirrhotic patients with chronic hepatitis B

2. Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?

3. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

4. Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection